Tools
ToolsReynolds, Catherine J., Pade, Corinna, Gibbons, Joseph M., Butler, David K., Otter, Ashley D., Menacho, Katia, Fontana, Marianna, Smit, Angelique, Sackville-West, Jane E., Cutino-Moguel, Teresa, Maini, Mala K., Chain, Benjamin, Noursadeghi, Mahdad, Brooks, Tim, Semper, Amanda, Manisty, Charlotte, Treibel, Thomas A., Moon, James C., Valdes, Ana M., McKnight, Áine, Altmann, Daniel M. and Boyton, Rosemary and UK COVIDsortium Immune Correlates Network, UK COVIDsortium Investigators (2021) Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 372 (6549). pp. 1418-1423. ISSN 0036-8075
Preview |
PDF (science.abh1282)
- Published Version
Available under License Creative Commons Attribution. Download (312kB) | Preview |
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided with the spread of variants of concern. We investigated whether single-dose vaccination, with or without prior infection, confers cross-protective immunity to variants. We analyzed T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated, or unchanged T cell responses, depending on human leukocyte antigen (HLA) polymorphisms. Single-dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.
| Item Type: | Article |
|---|---|
| Additional Information: | Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. SARS-CoV-2 nucleoprotein (100982) and SARS-CoV-2 spike (100979) are available from P. Cherepanov, Francis Crick Institute, UK, under a material transfer agreement with Centre for AIDS Reagents (CFAR), National Institute for Biological Standards and Control (NIBSC), UK. The SARS-CoV-2 B.1.1.7 isolate was obtained from NIBSC, thanks to the contribution of PHE Porton Down and S. Funnell. The nCoV19 isolate/UK ex South African/2021 lineage B.1.351 EVA catalog code 04V-04071 was obtained from European Virus Archive Global, PHE Porton Down. The SARS-CoV-2 Wuhan-Hu-1 Human 2019-nCoV Isolate EVA catalog code 026V-03883 was obtained from European Virus Archive Global, Charité – Universitätsmedizin Berlin. |
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 04 Mar 2025 14:30 |
| Last Modified: | 28 Mar 2025 13:14 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/98658 |
| DOI: | 10.1126/science.abh1282 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |